Loading company…
ID 212153667 · FY 2018–2024 · 7 years
კომპანიის ძირითად საქმიანობას წარმოადგენს ფარმაცევტული პრეპარატების წარმოება.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross Margin | 25.0% | 100.0% | 29.3% | 38.2% | 49.1% | 52.0% | 54.4% |
| EBITDA Margin | 2.5% | -8.0% | 2.1% | 8.0% | 3.1% | -4.4% | -8.3% |
| EBITDAR | 178 | -528 | 233 | 1,023 | 388 | -427 | -847 |
| EBITDAR Margin | 2.5% | -8.0% | 2.1% | 8.0% | 3.1% | -4.4% | -8.3% |
| EBIT Margin | -4.8% | -16.3% | -0.4% | 5.7% | 0.2% | -9.5% | -11.4% |
| Net Profit Margin | -10.4% | -14.3% | 2.0% | 7.3% | -1.3% | -11.5% | -12.6% |
| Operating Expense % of Sales | 22.5% | 108.0% | 27.1% | 30.3% | 46.0% | 56.4% | 62.8% |
| Returns | |||||||
| Return on Assets (ROA) | -6.6% | -9.5% | 1.6% | 6.2% | -1.0% | -6.0% | -6.7% |
| Return on Equity (ROE) | -8.5% | -12.3% | 2.1% | 6.9% | -1.0% | -6.5% | -7.0% |
| ROIC [EBIT / Invested Capital] | -4.5% | -14.4% | -0.5% | 6.1% | 0.2% | -5.7% | -6.9% |
| Leverage & liquidity | |||||||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | N/A | 0.00x | 0.00x | 0.00x | N/A | N/A |
| Equity-to-Assets | 77.5% | 77.4% | 77.3% | 90.6% | 96.4% | 92.5% | 95.3% |
| Net Debt | -932 | -179 | -471 | -1,637 | -1,292 | -1,093 | -1,264 |
| Cash & Equivalents | 932 | 179 | 471 | 1,637 | 1,292 | 1,093 | 1,264 |
| Total Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Efficiency & working capital | |||||||
| Inventory Turnover | N/A | 0.00x | 1.71x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | 1552876.1 | 213.2 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 2.80x | 8.62x | 11.12x | 5.07x | 4.17x | 3.42x | 2.65x |
| Days Sales Outstanding (DSO) | 130.6 | 42.3 | 32.8 | 71.9 | 87.6 | 106.6 | 137.6 |
| Payables Turnover | 2.11x | 0.00x | 2.54x | 5.64x | 10.55x | 3.36x | 5.21x |
| Days Payable Outstanding (DPO) | 172.8 | 818378.5 | 143.7 | 64.7 | 34.6 | 108.6 | 70.1 |
| Cash Conversion Cycle | -42.2 days | 734539.9 days | 102.4 days | 7.2 days | 53.0 days | -2.0 days | 67.5 days |
| Asset Turnover | 0.63x | 0.67x | 0.82x | 0.86x | 0.76x | 0.52x | 0.53x |
| Cash flow & dividends | |||||||
| Operating Cash Flow | N/A | -622 | 7,660 | 8,609 | 9,951 | 9,090 | 7,425 |
| Free Cash Flow (OCF − Capex proxy) | N/A | -753 | 248 | 1,201 | -55 | -105 | 233 |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | 3290.2% | 841.5% | 2564.7% | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).